Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells
about
Novel small molecule Raf kinase inhibitors for targeted cancer therapeuticsSynergistic inhibitory effect of hyperbaric oxygen combined with sorafenib on hepatoma cellsIon-current-based proteomic profiling of the retina in a rat model of Smith-Lemli-Opitz syndrome.A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer.Herbal extract SH003 suppresses tumor growth and metastasis of MDA-MB-231 breast cancer cells by inhibiting STAT3-IL-6 signaling.Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis.Alteration of SHP-1/p-STAT3 Signaling: A Potential Target for Anticancer Therapy.Function of UDP-glucuronosyltransferase 2B17 (UGT2B17) is involved in endometrial cancerDiindolylmethane suppresses ovarian cancer growth and potentiates the effect of cisplatin in tumor mouse model by targeting signal transducer and activator of transcription 3 (STAT3).In comparative analysis of multi-kinase inhibitors for targeted medulloblastoma therapy pazopanib exhibits promising in vitro and in vivo efficacy.The iron chelator Dp44mT inhibits hepatocellular carcinoma metastasis via N-Myc downstream-regulated gene 2 (NDRG2)/gp130/STAT3 pathway.Specific-detection of clinical samples, systematic functional investigations, and transcriptome analysis reveals that splice variant MUC4/Y contributes to the malignant progression of pancreatic cancer by triggering malignancy-related positive feedbSchedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinomaSorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10.Inhibition of mTOR kinase by AZD8055 can antagonize chemotherapy-induced cell death through autophagy induction and down-regulation of p62/sequestosome 1G-CSF Promotes Neuroblastoma Tumorigenicity and Metastasis via STAT3-Dependent Cancer Stem Cell Activation.Crosstalk of Sp1 and Stat3 signaling in pancreatic cancer pathogenesisPancreatic ductal adenocarcinoma: a review of immunologic aspects.Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growthEffects of cucurbitacins on cell morphology are associated with sensitization of renal carcinoma cells to TRAIL-induced apoptosis.Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathwaysThe monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant IIIMolecular targeted approaches for treatment of pancreatic cancer.Bax/Bak-independent mitochondrial depolarization and reactive oxygen species induction by sorafenib overcome resistance to apoptosis in renal cell carcinoma.Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody.Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling.Signal transducer and activator of transcription 3-mediated CD133 up-regulation contributes to promotion of hepatocellular carcinoma.A phase I, dose-finding study of sorafenib in combination with gemcitabine and radiation therapy in patients with unresectable pancreatic adenocarcinoma: a Grupo Español Multidisciplinario en Cáncer Digestivo (GEMCAD) study.Pathways and targets in hepatocellular carcinoma.The role of cell signalling in the crosstalk between autophagy and apoptosis.A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma.C2-ceramide enhances sorafenib-induced caspase-dependent apoptosis via PI3K/AKT/mTOR and Erk signaling pathways in HCC cells.Msi1 confers resistance to TRAIL by activating ERK in liver cancer cells.(E)-2,4-Bis(p-hydroxyphenyl)-2-butenal inhibits tumor growth via suppression of NF-κB and induction of death receptor 6.Protein phosphatase 2A impairs IFNα-induced antiviral activity against the hepatitis C virus through the inhibition of STAT1 tyrosine phosphorylation.Epidermal growth factor receptor signaling impairs the antiviral activity of interferon-alpha.The multikinase inhibitor Sorafenib displays significant antiproliferative effects and induces apoptosis via caspase 3, 7 and PARP in B- and T-lymphoblastic cells.Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axisHepatic stellate cell coculture enables sorafenib resistance in Huh7 cells through HGF/c-Met/Akt and Jak2/Stat3 pathways
P2860
Q28265862-E5040F62-FF7A-49CE-A06C-D1ADCC943EC3Q28539940-701FDA87-E511-484A-B766-0C82983B8DCFQ30559384-8FB15EA5-ABE6-4BA2-B7F9-28B08894EB86Q33394594-22881420-E622-4907-AD8F-4448809551F7Q33757639-84828DC1-1E67-4A09-AFD3-2312E18B3B31Q33838524-41722149-D8C4-4E03-B0A4-F722FB31F0C2Q33838824-5B86F77A-2E07-4CE8-BF0C-01E944B4CAB2Q34094975-1A4DFB62-7FBB-4369-892D-81F4549630BCQ34142384-2E96E037-1328-4C07-86B2-EC8D4A85B676Q34334533-20D0909A-1BBB-4EFE-8C2C-C814AE849432Q34483637-7A06E250-A610-406E-A765-B79EC4C5FF0DQ34537320-F4186DF5-E96B-48DE-BBB0-22975C8001EAQ34877852-8018E97C-3674-4C74-94DA-1F154647A1B7Q35404280-58BEBAE6-5F16-4FEB-9BFD-586A7AE72C26Q35561369-A3CEBD01-3123-4658-A303-C197BAFE4D21Q35562833-DE6E7091-B852-415D-999B-4146350D5143Q35752008-EA61B526-3B35-4609-BCD5-A848264AB8A5Q35840236-036E08DC-4EEE-4562-859C-6BD59ACF9D40Q35870682-01F1E96A-3970-4296-B244-EDD2719D34D3Q35928707-A55D5516-8A9F-4A2E-AE39-98D04DE93FA7Q35938641-A638393B-A585-41FF-A653-340415A7A040Q35963384-FDD8ADFC-843A-4130-AC26-3709707F15EFQ36088178-8B7496E6-0285-4422-B852-415967E20015Q36174910-17B66130-4A79-43A9-9418-4CCB66322185Q36268430-2ADAED74-2960-4713-A04F-371E7F6D464EQ36629288-A4980828-4844-4FEC-8148-10E417C4357CQ37040669-DD78A335-3751-4915-8E03-848C954B33A6Q37309060-468AC060-3014-4413-8F31-929A0CFBDD26Q37458491-F6C18FD1-826D-49F4-9125-FA132A6CFAC1Q38062022-BF5B9F25-0591-46B6-9C4B-496E7C2332D3Q38168965-1B9D8BC4-B30F-42C2-B118-15C7617F5DC2Q38708598-5691DCFE-3FA4-4213-8440-4BC91B5C5A2CQ38733769-D9C7DB13-DDA3-4D08-BED7-E2A0BC17C6D5Q38902765-AE425DA3-30FC-4800-9CE1-AE828BB325F8Q39093846-D4F04284-092C-44CF-8A09-36ACE3C51F0CQ39116339-3A376630-9006-4853-83E8-FE89DFFAABDBQ39177270-678B42CF-7ABB-4082-BF89-570A69419928Q39643630-7131CCC9-B9B4-4A74-B74D-2E2F3100F582Q42106395-41051AC2-1082-4F44-8153-29AC53EB013BQ42181154-B23551A1-5C19-43CE-B9BE-9F6108F5F0DE
P2860
Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Sorafenib inhibits STAT3 activ ...... human pancreatic cancer cells
@ast
Sorafenib inhibits STAT3 activ ...... human pancreatic cancer cells
@en
type
label
Sorafenib inhibits STAT3 activ ...... human pancreatic cancer cells
@ast
Sorafenib inhibits STAT3 activ ...... human pancreatic cancer cells
@en
prefLabel
Sorafenib inhibits STAT3 activ ...... human pancreatic cancer cells
@ast
Sorafenib inhibits STAT3 activ ...... human pancreatic cancer cells
@en
P2860
P1476
Sorafenib inhibits STAT3 activ ...... human pancreatic cancer cells
@en
P2093
Frank A Sinicrope
Shengbing Huang
P2860
P304
P356
10.1158/1535-7163.MCT-09-1004
P577
2010-03-02T00:00:00Z